Downregulation of cyclooxygenase-1 is involved in gastric mucosal apoptosis via death signaling in portal hypertensive rats

Cell Research

Volumn 19, Issue 11, 2009, Pages 1269-1278

  Wu, Bin ^a   Zeng, Lixian ^a   Lin, Ying ^a   Wen, Zhuofu ^a   Chen, Guihua ^a   Iwakiri, Ryuichi ^b   Fujimoto, Kazuma ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SAGA UNIVERSITY   (Japan)

Author keywords

Caspase 3; Caspase 8; Fas ligand, tumor necrosis factor related poptosis inducing ligand; Tumor necrosis factor

Indexed keywords

CASP3 PROTEIN, RAT; CASP8 PROTEIN, RAT; CASPASE 3; CASPASE 8; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME C; FAS LIGAND; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL; APOPTOSIS; ARTICLE; BLOOD; CELL PROLIFERATION; DOWN REGULATION; ENZYMOLOGY; EXPERIMENTAL LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PORTAL HYPERTENSION; RAT; SIGNAL TRANSDUCTION; STOMACH MUCOSA;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 8; CELL PROLIFERATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROMES C; DINOPROSTONE; DOWN-REGULATION; FAS LIGAND PROTEIN; GASTRIC MUCOSA; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, EXPERIMENTAL; RATS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 70449525570     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2009.97     Document Type: Article

References (46)

1. Kinjo N, Kawanaka H, Akahoshi T, et al. Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications. Am J Physiol Gastrointest Liver Physiol 2008; 295:G1016-G1024.
2. Ichikawa Y, Tarnawski A, Sarfeh IJ, Ishikawa T, Shimada H. Distorted microangioarchitecture and impaired angiogenesis in gastric mucosa of portal hypertensive rats. Gastroenterology 1994; 106:702-708.
3. Ishikawa T, Sarfeh IJ, Tarnawski A, Golshan R, Douglas T, Sugiyama M. Epidermal growth factor protects portal hypertensive gastric mucosa in ischemia/reperfusion: the role of capillary endothelia and prostaglandins. Surgery 1992; 112:341-346.
4. Kawanaka H, Tomikawa M, Jones MK, et al. Portal hypertensive gastric mucosa has reduced activation of MAP kinase (ERK2) in response to alcohol injury: a key to impaired healing? FASEB J 2000; 15:574-576.
5. Pateron D, Tazi KA, Sogni P, et al. Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. Gastroenterology 2000; 119:196-200.
6. Yokoyama Y, Baveja R, Sonin N, Clemens MG, Zhang JX. Hepatic neovascularization after partial portal vein ligation: novel mechanism of chronic regulation of blood flow. Am J Physiol Gastrointest Liver Physiol 2001; 280:G21-G31.
7. Yokoyama Y, Wawrzyniak A, Baveja R, Sonin N, Clemens MG, Zhang JX. Altered endothelin receptor expression in prehepatic portal hypertension predisposes the liver to microcirculatory dysfunction in rats. J Hepatol 2001; 35:29-36.
8. McCormack TT, Sims J, Eyre-Brook I, et al. Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy? Gut 1985; 26:1226-1232.
9. Arakawa T, Satoh H, Fukuda T, Nakamura H, Kobayashi K. Endogenous prostaglandin E2 in gastric mucosa of patients with alcoholic cirrhosis and portal hypertension. Gastroenterology 1987; 93:135-140.
10. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 2008; 88:1547-1565.
11. Camara PR, Ferraz GJ, Franco-Penteado CF, et al. Ablation of primary afferent neurons by neonatal capsaicin treatment reduces the susceptibility of the portal hypertensive gastric mucosa to ethanol-induced injury in cirrhotic rats. Eur J Pharmacol 2008; 589:245-250.
12. Skill NJ, Theodorakis NG, Wang YN, Wu JM, Redmond EM, Sitzmann JV. Role of cyclooxygenase isoforms in prostacyclin biosynthesis and murine prehepatic portal hypertension. Am J Physiol Gastrointest Liver Physiol 2008; 295:G953-G964.
13. Beck PL, Lee SS, McKnight GW, Wallace JL. Characterization of spontaneous and ethanol-induced gastric damage in cirrhotic rats. Gastroenterology 1992; 103:1048-1055.
14. Payen JL, Cales P, Pienkowski P, et al. Weakness of mucosal barrier in portal hypertensive gastropathy of alcoholic cirrhosis. Effects of propranolol and enprostil. J Hepatol 1995; 23:689-696.
15. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase- 1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99:13926-13931.
16. Kargman S, Charleson S, Cartwright M, et al. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996; 111:445-454.
17. Schwab JM, Beiter T, Linder JU, et al. COX-3--a virtual pain target in humans? FASEB J 2003; 17:2174-2175.
18. Chen NJ, Chio II, Lin WJ, et al. Beyond tumor necrosis factor receptor: TRADD signaling in toll-like receptors. Proc Natl Acad Sci USA 2008; 105:12429-12434.
19. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114:181-190.
20. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/ Fas) signaling pathways. EMBO J 1998; 17:1675-1687.
21. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-163.
22. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012.
23. Kaviani A, Ohta M, Itani R, Sander F, Tarnawski AS, Sarfeh IJ. Tumor necrosis factor-alpha regulates inducible nitric oxide synthase gene expression in the portal hypertensive gastric mucosa of the rat. J Gastrointest Surg 1997; 1:371-376.
24. Munoz J, Albillos A, Perez-Paramo M, Rossi I, Alvarez-Mon M. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol Gastrointest Liver Physiol 1999; 276:G687-G693.
25. Deviere J, Content J, Denys C, et al. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 1990; 11:628-634.
26. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991; 13:267-276.
27. Barnhart BC, Peter ME. The TNF receptor 1: a split personality complex. Cell 2003; 114:148-150.
28. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997; 7:821-830.
29. Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerg ing TRAIL receptor family. J Exp Med 1997; 186:1165-1170.
30. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-14367.
31. Mizoguchi E, Mizoguchi A, Takedatsu H, et al. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology 2002; 122:134-144.
32. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277:815-818.
33. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-113.
34. Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997; 7:831-836.
35. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAILR2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16:5386-5397.
36. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17:331-367.
37. Wu B, Qiu W, Wang P, et al. p53 independent induction of PUMA mediates intestinal apoptosis in response to ischaemiareperfusion. Gut 2007; 56:645-654.
38. Wu B, Iwakiri R, Ootani A, Fujise T, Tsunada S, Fujimoto K. Platelet-activating factor promotes mucosal apoptosis via FasL-mediating caspase-9 active pathway in rat small intestine after ischemia-reperfusion. FASEB J 2003; 17:1156-1158.
39. Wu B, Ootani A, Iwakiri R, et al. Ischemic preconditioning attenuates ischemia-reperfusion-induced mucosal apoptosis by inhibiting mitochondria-dependent pathway in rat small intestine. Am J Physiol Gastrointest Liver Physiol 2004; 286:G580-G587.
40. Wu B, Iwakiri R, Tsunada S, et al. iNOS enhances rat intestinal apoptosis after ischemia-reperfusion. Free Radic Biol Med 2002; 33:649-658.
41. Fiorucci S, De Lima OM Jr, Mencarelli A, et al. Cyclooxygenase- 2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 2002; 123:1598-1606.
42. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAIDinduced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119:706-714.
43. Potenza MA, Botrugno OA, De Salvia MA, et al. Endothelial COX-1 and -2 differentially affect reactivity of MVB in portal hypertensive rats. Am J Physiol Gastrointest Liver Physiol 2002; 283:G587-G594.
44. Ou XW, Wang H, De Plaen IG, Rozenfeld RA, Hsueh W. Neuronal nitric oxide synthase (NOS) regulates the expression of inducible NOS in rat small intestine via modulation of nuclear factor kappa B. FASEB J 2001; 15:439-446.
45. Wu D, Wallen HD, Nunez G. Interaction and regulation of subcellular localization of CED-4 by CED-9. Science 1997; 275:1126-1129.
46. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275:1129-1132.